

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1136.0020001/JAG/ARB	APPLICATION NO. 08/487,992
	APPLICANTS Hallenbeck <i>et al.</i>	
	FILING DATE June 7, 1995	GROUP to be assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
PT	AR	10	Gordon, E.M. <i>et al.</i> , Gene Therapy using retroviral Vectors, <i>Current Opinion in Biotechnology</i> 5:611-616 (1994)
PT	AS	10	Kaneko <i>et al.</i> , Adenovirus-mediated Gene Therapy of Hepatocellular Carcinoma Using Cancer specific Gene Expression, <i>Cancer Research</i> 55:5283-5287 (1995)
PT	AT	10	Missero, C. <i>et al.</i> , Skin-specific Expression of a Truncated <i>E1a</i> Oncoprotein Binding to p105-Rb Leads to Abnormal Hair Follicle Maturation Without Increased Epidermal Proliferation, <i>Journal of Cell Biology</i> 121(5):1109-1120 (1993)

EXAMINER	<i>PT</i>	DATE CONSIDERED	12/5/98
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1136.0020001/JAG/ABB	APPLICATION NO. 08/487,992
	APPLICANTS Hallenbeck et al.	
	FILING DATE June 7, 1995	GROUP to be assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	11	Pulsieux et al., p53 as a Growth Suppressor Gene in HBV-related Hepatocellular Carcinoma Cells, <i>Oncogene</i> 8: 487-490 (1993)	
AS	11	Shimizu et al., RB Protein Status and Clinical Correlation from 171 Cell Lines Representing Lung Cancer, Extrapulmonary Small Cell Carcinoma, and Mesothelioma, <i>Oncogene</i> 9:2441-2448 (1994)	
AT	11		



EXAMINER	DATE CONSIDERED
<i>P. J. M. [Signature]</i>	12/5/96


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1136.0020001/JAG/ARB		APPLICATION NO. 08/487,992	
				APPLICANT Hallenbeck <i>et al.</i>			
				FILING DATE June 7, 1995		GROUP to be assigned	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,416,017	05/16/95	Burton <i>et al.</i>	435	240.2	03/25/93
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	8	
	AS	8	Harris, J.D. <i>et al.</i> , Gene Therapy for Cancer Using Tumor-Specific Prodrug Activation, <i>Gene Therapy</i> 1(3):170-175 (May, 1994)
	AT	8	Nakamura, Y. <i>et al.</i> , Adoptive Immunotherapy with Murine Tumor-Specific T Lymphocytes Engineered to Secrete Interleukin 2, <i>Cancer Research</i> 54, 5757-5760 (November 15, 1994)



EXAMINER 	DATE CONSIDERED 12/5/96
--	-------------------------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1136.0020001/JAG/ARB		APPLICATION NO. 08/487,992	
				APPLICANT Hallenbeck <i>et al.</i>			
				FILING DATE June 7, 1995		GROUP to be assigned	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2						
	AB2						
	AC2						
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2						Yes No
	AM2						Yes No
	AN2						Yes No
	AO2						Yes No
	AP2						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	2	Vile, R. <i>et al.</i> , Gene Therapy and Cytokines, BACR/ACP Annual Meeting, March 27-30, 1994 (abstract) <i>British J.Cancer (Supplement)</i> p. 3, S7.(March 21, 1994)
	AS	2	Vile, R.G. <i>et al.</i> , Direct Gene Transfer to Tumour Cells <i>in Vivo</i> , Second Meeting of The European Working Group on Human Gene Transfer and Therapy (abstract), <i>Gene Therapy Vol.1(Supplement 2)</i> A23 (November 21, 1994).
	AT	2	

EXAMINER 	DATE CONSIDERED 12/5/96
--	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1136.0020001/JAG/ARBAPPLICATION NO.
08/487,992APPLICANTS
Hallenbeck et al.FILING DATE
June 7, 1995GROUP
to be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PT	AR	1	Babiss, L.E. et al., Cellular Promoters Incorporated into the Adenovirus Genome, Effect of Viral DNA Replication on Endogenous and Exogenous Gene Transcription, <i>J. Mol. Biol.</i> 193:643-650 (1987)
PT	AS	1	Blaese, R.M. et al., In situ Delivery of Suicide Genes for Cancer Treatment, <i>European Journal of Cancer</i> 30A(8):1190-1193 (August, 1994)
PT	AT	1	Cornelis, J.J. et al., Transformation of Human Fibroblasts by Ionizing Radiation, a Chemical Carcinogen, or Simian Virus 40 Correlates with an Increase in Susceptibility to the Autonomous Parvoviruses H-1 Virus and Minute Virus of Mice, <i>Journal of Virology</i> 62(5):1679-1686 (1988)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1136.0020001/JAG/ARBAPPLICATION NO.
08/487,992APPLICANTS
Hallenbeck et al.FILING DATE
June 7, 1995GROUP
to be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2						
	AB2						
	AC2						
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2						Yes No
	AM2						Yes No
	AN2						Yes No
	AO2						Yes No
	AP2						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PT	AR	2	Dillon, W., Regulating Gene Expression in Gene Therapy, <i>Trends Biotechnol.</i> 11:167-173 (May, 1993)
PT	AS	2	Dynan, W.S., Modularity in Promoters and Enhancers, <i>Cell</i> 58:1-4 (1989)
PT	AT	2	Fattaey, A. et al., Replication of Adenovirus Mutants in Human Cancer Cells, from Abstracts of papers presented at the 1994 meeting on Molecular Biology of Papovaviruses & Adenoviruses, August 17-August 21, 1994, Cold Spring Laboratory, Cold Spring Harbor, New York.

EXAMINER <i>PT may</i>	DATE CONSIDERED 12/5/96
------------------------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1136.0020001/JAG/ARBAPPLICATION NO.
08/487,992APPLICANTS
Hallenbeck et al.FILING DATE
June 7, 1995GROUP
to be assigned




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	3	Friedman, J.M. et al., Cellular Promoters Incorporated into the Adenovirus Genome: Cell Specificity of Albumin and Immunoglobulin Expression, <i>Molecular and Cellular Biology</i> 6(11):3791-3797 (1986)
	AS	3	Graham, F.L., Growth of 293 Cells in Suspension Culture, <i>J. gen. Virol.</i> 68:937-940 (1987)
	AT	3	Hitt, M.M. et al., Adenovirus E1A under the Control of Heterologous Promoters: Wide Variation in E1A Expression Levels Has Little Effect on Virus Replication, <i>Virology</i> 179:667-678 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1136.0020001/JAG/ARB		APPLICATION NO. 08/487,992	
				APPLICANTS Hallenbeck et al.			
				FILING DATE June 7, 1995		GROUP to be assigned	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	4	Huber, B.E. et al., Retroviral-mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy, <i>Proc. Natl. Acad. Sci. USA</i> 88:8039-8043 (1991)
	AS	4	Lewin, B., Oncogenic Conversion by Regulatory Changes in Transcription Factors, <i>Cell</i> 64:303-312 (1991)
	AT	4	Manome, Y. et al., Enhancer Sequences of the <i>DF3</i> Gene Regulate Expression of the Herpes Simplex Virus Thymidine Kinase Gene and Confer Sensitivity of Human Breast Cancer Cells to Ganciclovir, <i>Cancer Research</i> 54:5408-5413 (October, 1994)

EXAMINER	DATE CONSIDERED <u>12/5/96</u>
----------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1136.0020001/JAG/ARBAPPLICATION NO.
08/487,992APPLICANTS
Hallenbeck et al.FILING DATE
June 7, 1995GROUP
to be assigned




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	5	Ohno, T. et al., Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury, <i>Science</i> 265:781-784 (August, 1994)
	AS	5	Osaki, T. et al., Gene Therapy for Carcinoembryonic Antigen-producing Human Lung Cancer Cells by Cell Type-specific Expression of Herpes Simplex Virus Thymidine Kinase Gene, <i>Cancer Research</i> 54:5258-5261 (October, 1994)
	AT	5	Russell, S.J., Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects, <i>European Journal of Cancer</i> 30A(8):1165-1171 (August, 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1136.0020001/JAG/ARBAPPLICATION NO.
08/487,992APPLICANTS
Hallenbeck et al.FILING DATE
June 7, 1995GROUP
to be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PT	AR	6	Russell, S.J. et al., Transformation-Dependent Expression of Interleukin Genes Delivered by a Recombinant Parvovirus, <i>Journal of Virology</i> 66(5):2821-2828 (1992)
PT	AS	6	Salmons, B. et al., Targeting of Retroviral Vectors for Gene Therapy, <i>Human Gene Therapy</i> 4:129-141 (April, 1993)
AA	AT	6	Schrewe, H. et al., Cloning of the Complete Gene for Carcinoembryonic Antigen: Analysis of Its Promoter Indicates a Region Conveying Cell Type-Specific Expression, <i>Molecular and Cellular Biology</i> 10(6):2738-2748 (1990)

EXAMINER

DATE CONSIDERED

12/5/96

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1136.0020001/JAG/ARBAPPLICATION NO.
08/487,992APPLICANTS
Hallenbeck et al.FILING DATE
June 7, 1995GROUP
to be assigned




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Z	Sikora, K., Genetic Approaches to Cancer Therapy, <i>Gene Therapy</i> 1:149-151 (January, 1994)
	AS	Z	Vile, R. et al., In Vitro and in Vivo Targeting of Gene Expression to Melanoma Cells, <i>Cancer Research</i> 53:962-967 (March, 1993)
	AT	Z	Vile, R. et al., Use of Tissue-specific Expression of the Herpes Simplex Virus Thymidine Kinase Gene to Inhibit Growth of Established Murine Melanomas following Direct Intratumoral Injection of DNA, <i>Cancer Research</i> 53:3860-3864 (September, 1993)

EXAMINER 	DATE CONSIDERED 12/5/96
--	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1136.0020001/JAG/ARBAPPLICATION NO.
08/487,992APPLICANTS
Hallenbeck et al.FILING DATE
June 7, 1995GROUP
to be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PT	AR	8	Yang, Y. et al., MHC Class 1-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant Adenoviruses, <i>Immunity</i> 1:433-442 (August, 1994)
	AS	8	
	AT	8	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1136.0020001/JAG/ARB	APPLICATION NO. 08/487,992
	APPLICANTS Hallenbeck <i>et al.</i>	
	FILING DATE June 7, 1995	GROUP to be assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>RT</i>	AA1						
	AB1	5,436,146	7/25/95	Shenk <i>et al.</i>			1/21/93
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
<i>RT</i>	AM1	WO 90/05180	5/17/90	PCT			Yes No
<i>RT</i>	AN1	WO 95/11984	5/4/95	PCT			Yes No
<i>RT</i>	AO1	WO 95/12660	5/11/95	PCT			Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	
	AS	2	
<i>RT</i>	AT	2	Fujiwara <i>et al.</i> , A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis, <i>Cancer Research</i> 53:4129-4133 (1993)

EXAMINER <i>RT</i>	DATE CONSIDERED 12/5/96
--------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1136.0020001/JAG/ARB	APPLICATION NO. 08/487,992
	APPLICANTS Hallenbeck <i>et al.</i>	
	FILING DATE June 7, 1995	GROUP to be assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
<i>R.T.</i>	AL1	WO 94/18992	9/1/94	PCT			Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	1	
	AS	1	
	AT	1	

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>12/5/96</i>
-----------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.